TY  - JOUR 
AU  - Rehues, P.
AU  - Girona, J.
AU  - Guardiola, M.
AU  - Plana, N.
AU  - Scicali, R.
AU  - Piro, S.
AU  - Muñiz-Grijalvo, O.
AU  - Díaz Díaz, José Luis
AU  - Recasens, L.
AU  - Pinyol, M.
AU  - Rosales, R.
AU  - Esteban, Y.
AU  - Amigó, N.
AU  - Masana, L.
AU  - Ibarretxe, D.
AU  - Ribalta, J.
PY  - 2023
SN  - 1422-0067
UR  - http://hdl.handle.net/20.500.11940/21839
AB  - Highlights: What are the main findings? PCSK9 inhibition significantly reduces 1H-NMR glycoprotein signals and does not affect hsCRP levels. Apolipoprotein C-III and triglycerides are also decreased by iPCSK9. The decrease in glycoproteins correlates...
LA  - eng
KW  - Humans
KW  - Proprotein Convertase 9
KW  - PCSK9 Inhibitors
KW  - Apolipoprotein C-III
KW  - Cardiovascular Diseases
KW  - C-Reactive Protein
KW  - Proton Magnetic Resonance Spectroscopy
KW  - Risk Factors
KW  - Cholesterol
KW  - Cholesterol, LDL
KW  - Triglycerides
KW  - Magnetic Resonance Spectroscopy
KW  - Lipoproteins
KW  - Inflammation
KW  - Anti-Inflammatory Agents
KW  - Glycoproteins
KW  - Heart Disease Risk Factors
TI  - PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk
DO  - 10.3390/ijms24032319
T2  - International Journal of Molecular Sciences
KW  - AS A Coruña
KW  - CHUAC
VL  - 24
ER  -